D
D. E. Thompson
Researcher at University of Minnesota
Publications - 6
Citations - 1906
D. E. Thompson is an academic researcher from University of Minnesota. The author has contributed to research in topics: Osteoporosis & Dosing. The author has an hindex of 6, co-authored 6 publications receiving 1861 citations.
Papers
More filters
Journal ArticleDOI
Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group.
David J. Hosking,C. E. D. Chilvers,C. Christiansen,Pernille Ravn,R. D. Wasnich,Philip D. Ross,Michael R. McClung,Ana Balske,D. E. Thompson,M. Daley,A. J. Yates +10 more
TL;DR: Estrogen-replacement therapy prevents osteoporosis in postmenopausal women by inhibiting bone resorption, but the balance between its long-term risks and benefits remains unclear.
Journal ArticleDOI
Prevalent Vertebral Deformities Predict Mortality and Hospitalization in Older Women with Low Bone Mass
Kristine E. Ensrud,Kristine E. Ensrud,D. E. Thompson,Jane A. Cauley,Michael C. Nevitt,Deborah M. Kado,Marc C. Hochberg,Arthur C. Santora,Dennis M. Black +8 more
TL;DR: To determine the relationship between prevalent vertebral deformities and the risk of mortality and hospitalization in older women with low bone mass, a large number of them are female.
Journal ArticleDOI
Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis
Thomas J. Schnitzer,Henry G. Bone,G. Crepaldi,S. Adami,Michael R. McClung,Douglas P. Kiel,D. Felsenberg,Robert R. Recker,R. P. Tonino,Christian Roux,A. Pinchera,A. J. Foldes,Susan L. Greenspan,Michael A. Levine,Ronald Emkey,A Santora,Amarjot Kaur,D. E. Thompson,J. Yates,John J. Orloff +19 more
TL;DR: It is concluded that the alendronate 70 mg once-weekly dosing regimen will provide patients with a more convenient, therapeutically equivalent alternative to daily dosing, and may enhance compliance and long-term persistence with therapy.
Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group.
Thomas J. Schnitzer,Henry G. Bone,G. Crepaldi,S. Adami,Michael R. McClung,Douglas P. Kiel,Dieter Felsenberg,Robert R. Recker,R. P. Tonino,Christian Roux,A. Pinchera,A. J. Foldes,Susan L Greenspan,Michael A. Levine,Ronald Emkey,A C Santora nd,Amarjot Kaur,D. E. Thompson,John Yates,John J. Orloff +19 more
TL;DR: It is concluded that the alendronate 70 mg once-weekly dosing regimen will provide patients with a more convenient, therapeutically equivalent alternative to daily dosing, and may enhance compliance and long-term persistence with therapy.
Journal ArticleDOI
Prevention of Bone Loss With Alendronate in Postmenopausal Women Under 60 Years of Age
David J. Hosking,C. E. D. Chilvers,C. Christiansen,Pernille Ravn,Richard D. Wasnich,Philip D. Ross,Michael R. McClung,Ana Balske,D. E. Thompson,M. Daley,A. J. Yates +10 more
TL;DR: Alendronate prevents bone loss in postmenopausal women under 60 years of age to nearly the same extent as estrogen-progestin and was well tolerated, with a safety profile similar to that of placebo or estrogen- Progestin.